可視化

発行年ごと論文数

著者正規化top50

著者正規化top50の共著関係

タイトル語top50

タイトル語top50の共起

ジャーナル一覧

ジャーナル分野比率


論文リスト

doi title author source_title year
3142 10.1016/j.annonc.2020.04.010 Updated Efficacy Results From The Javelin Renal 101 Trial: First-Line Avelumab Plus Axitinib Versus Sunitinib In Patients With Advanced Renal Cell Carcinoma Choueiri, T.K.; Motzer, R.J.; Rini, B.I.; Haanen, J.; Campbell, M.T.; Venugopal, B.; Kollmannsberger, C.; Gravis-Mescam, G.; Uemura, M.; Lee, J.L.; Grimm, M.-O.; Gurney, H.; Schmidinger, M.; Larkin, J.; Atkins, M.B.; Pal, S.K.; Wang, J.; Mariani, M.; Krishnaswami, S.; Cislo, P.; Chudnovsky, A.; Fowst, C.; Huang, B.; Di Pietro, A.; Albiges, L. Annals Of Oncology 2020
3147 10.1016/j.annonc.2020.08.2257 696O_Pr Nivolumab + Cabozantinib Vs Sunitinib In First-Line Treatment For Advanced Renal Cell Carcinoma: First Results From The Randomized Phase Iii Checkmate 9Er Trial Choueiri, T.K.; Powles, T.; Burotto, M.; Bourlon, M.T.; Zurawski, B.; Oyervides Juarez, V.M.; Hsieh, J.J.; Basso, U.; Shah, A.Y.; Suarez, C.; Hamzaj, A.; Barrios, C.H.; Richardet, M.; Pook, D.; Tomita, Y.; Escudier, B.; Zhang, J.; Simsek, B.; Apolo, A.B.; Motzer, R.J. Annals Of Oncology 2020
5449 10.1016/j.ejca.2018.11.031 Second-Line Targeted Therapies After Nivolumab-Ipilimumab Failure In Metastatic Renal Cell Carcinoma Auvray, Marie, 0000-0002-1258-861X; Auclin, Edouard; Barthelemy, Philippe; Bono, Petri; Kellokumpu-Lehtinen, Pirkko; Gross-Goupil, Marine; De Velasco, Guillermo, 0000-0002-8075-0666; Powles, Thomas; Mouillet, Guillaume, 0000-0002-2288-7461; Vano, Yann-Alexandre; Gravis, Gwenaelle; Mourey, Loic; Priou, Franck; Rolland, Frederic; Escudier, Bernard; Albiges, Laurence European Journal Of Cancer 2019
5994 10.1016/j.eururo.2019.05.022 Updated European Association Of Urology Guidelines On Renal Cell Carcinoma: Immune Checkpoint Inhibition Is The New Backbone In First-Line Treatment Of Metastatic Clear-Cell Renal Cell Carcinoma Albiges, Laurence; Powles, Tom; Staehler, Michael; Bensalah, Karim; Giles, Rachel H.; Hora, Milan; Kuczyk, Markus A.; Lam, Thomas B.; Ljungberg, Borje; Marconi, Lorenzo; Merseburger, Axel S.; Volpe, Alessandro; Abu-Ghanem, Yasmin; Dabestani, Saeed; Fernandez-Pello, Sergio; Hofmann, Fabian; Kuusk, Teele; Tahbaz, Rana; Bex, Axel European Urology 2019
10119 10.1016/s0140-6736(19)30723-8 Atezolizumab Plus Bevacizumab Versus Sunitinib In Patients With Previously Untreated Metastatic Renal Cell Carcinoma (Immotion151): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial Rini, Brian I; Powles, Thomas; Atkins, Michael B; Escudier, Bernard; Mcdermott, David F; Suarez, Cristina; Bracarda, Sergio; Stadler, Walter M; Donskov, Frede; Lee, Jae Lyun; Hawkins, Robert; Ravaud, Alain; Alekseev, Boris; Staehler, Michael; Uemura, Motohide; De Giorgi, Ugo; Mellado, Begona; Porta, Camillo; Melichar, Bohuslav; Gurney, Howard; Bedke, Jens; Choueiri, Toni K; Parnis, Francis; Khaznadar, Tarik; Thobhani, Alpa; Li, Shi; Piault-Louis, Elisabeth; Frantz, Gretchen; Huseni, Mahrukh; Schiff, Christina; Green, Marjorie C; Motzer, Robert J The Lancet 2019
10266 10.1016/s1470-2045(18)30648-x Genomically Annotated Risk Model For Advanced Renal-Cell Carcinoma: A Retrospective Cohort Study Voss, Martin H; Reising, Albert; Cheng, Yuan; Patel, Parul; Marker, Mahtab; Kuo, Fengshen; Chan, Timothy A; Choueiri, Toni K; Hsieh, James J; Hakimi, A Ari; Motzer, Robert J The Lancet Oncology 2018
10272 10.1016/s1470-2045(18)30778-2 Patient-Reported Outcomes Of Patients With Advanced Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab Versus Sunitinib (Checkmate 214): A Randomised, Phase 3 Trial Cella, David; Grunwald, Viktor; Escudier, Bernard; Hammers, Hans J; George, Saby; Nathan, Paul; Grimm, Marc-Oliver; Rini, Brian I; Doan, Justin; Ivanescu, Cristina; Paty, Jean; Mekan, Sabeen; Motzer, Robert J The Lancet Oncology 2019
10299 10.1016/s1470-2045(19)30413-9 Nivolumab Plus Ipilimumab Versus Sunitinib In First-Line Treatment For Advanced Renal Cell Carcinoma: Extended Follow-Up Of Efficacy And Safety Results From A Randomised, Controlled, Phase 3 Trial Motzer, Robert J; Rini, Brian I; Mcdermott, David F; Aren Frontera, Osvaldo; Hammers, Hans J; Carducci, Michael A; Salman, Pamela; Escudier, Bernard; Beuselinck, Benoit; Amin, Asim; Porta, Camillo; George, Saby; Neiman, Victoria; Bracarda, Sergio; Tykodi, Scott S; Barthelemy, Philippe; Leibowitz-Amit, Raya; Plimack, Elizabeth R; Oosting, Sjoukje F; Redman, Bruce; Melichar, Bohuslav; Powles, Thomas; Nathan, Paul; Oudard, Stephane; Pook, David; Choueiri, Toni K; Donskov, Frede; Grimm, Marc-Oliver; Gurney, Howard; Heng, Daniel Y C; Kollmannsberger, Christian K; Harrison, Michael R; Tomita, Yoshihiko; Duran, Ignacio; Grunwald, Viktor; Mchenry, M Brent; Mekan, Sabeen; Tannir, Nizar M The Lancet Oncology 2019
10313 10.1016/s1470-2045(19)30735-1 Tivozanib Versus Sorafenib In Patients With Advanced Renal Cell Carcinoma (Tivo-3): A Phase 3, Multicentre, Randomised, Controlled, Open-Label Study Rini, Brian I; Pal, Sumanta K; Escudier, Bernard J; Atkins, Michael B; Hutson, Thomas E; Porta, Camillo; Verzoni, Elena; Needle, Michael N; Mcdermott, David F The Lancet Oncology 2020
10341 10.1016/s1470-2045(20)30436-8 Pembrolizumab Plus Axitinib Versus Sunitinib Monotherapy As First-Line Treatment Of Advanced Renal Cell Carcinoma (Keynote-426): Extended Follow-Up From A Randomised, Open-Label, Phase 3 Trial Powles, Thomas; Plimack, Elizabeth R; Soulieres, Denis; Waddell, Tom; Stus, Viktor; Gafanov, Rustem; Nosov, Dmitry; Pouliot, Frederic; Melichar, Bohuslav; Vynnychenko, Ihor; Azevedo, Sergio J; Borchiellini, Delphine; Mcdermott, Raymond S; Bedke, Jens; Tamada, Satoshi; Yin, Lina; Chen, Mei; Molife, L Rhoda; Atkins, Michael B; Rini, Brian I The Lancet Oncology 2020
14642 10.1038/s41591-018-0053-3 Clinical Activity And Molecular Correlates Of Response To Atezolizumab Alone Or In Combination With Bevacizumab Versus Sunitinib In Renal Cell Carcinoma Mcdermott, David F.; Huseni, Mahrukh A.; Atkins, Michael B.; Motzer, Robert J.; Rini, Brian I.; Escudier, Bernard; Fong, Lawrence; Joseph, Richard W.; Pal, Sumanta K.; Reeves, James A.; Sznol, Mario; Hainsworth, John; Rathmell, W. Kimryn; Stadler, Walter M.; Hutson, Thomas; Gore, Martin E.; Ravaud, Alain; Bracarda, Sergio; Suarez, Cristina; Danielli, Riccardo; Gruenwald, Viktor; Choueiri, Toni K.; Nickles, Dorothee; Jhunjhunwala, Suchit; Piault-Louis, Elisabeth; Thobhani, Alpa; Qiu, Jiaheng; Chen, Daniel S.; Hegde, Priti S.; Schiff, Christina; Fine, Gregg D.; Powles, Thomas Nature Medicine 2018
16031 10.1056/nejmoa1712126 Nivolumab Plus Ipilimumab Versus Sunitinib In Advanced Renal-Cell Carcinoma Motzer, Robert J.; Tannir, Nizar M.; Mcdermott, David F.; Aren Frontera, Osvaldo; Melichar, Bohuslav; Choueiri, Toni K.; Plimack, Elizabeth R.; Barthelemy, Philippe; Porta, Camillo; George, Saby; Powles, Thomas; Donskov, Frede; Neiman, Victoria; Kollmannsberger, Christian K.; Salman, Pamela; Gurney, Howard; Hawkins, Robert; Ravaud, Alain; Grimm, Marc-Oliver; Bracarda, Sergio; Barrios, Carlos H.; Tomita, Yoshihiko; Castellano, Daniel; Rini, Brian I.; Chen, Allen C.; Mekan, Sabeen; Mchenry, M. Brent; Wind-Rotolo, Megan; Doan, Justin; Sharma, Padmanee; Hammers, Hans J.; Escudier, Bernard New England Journal Of Medicine 2018
16096 10.1056/nejmoa1816047 Avelumab Plus Axitinib Versus Sunitinib For Advanced Renal-Cell Carcinoma Motzer, Robert J.; Penkov, Konstantin; Haanen, John; Rini, Brian; Albiges, Laurence; Campbell, Matthew T.; Venugopal, Balaji; Kollmannsberger, Christian; Negrier, Sylvie; Uemura, Motohide; Lee, Jae L.; Vasiliev, Aleksandr; Miller, Wilson H.; Gurney, Howard; Schmidinger, Manuela; Larkin, James; Atkins, Michael B.; Bedke, Jens; Alekseev, Boris; Wang, Jing; Mariani, Mariangela; Robbins, Paul B.; Chudnovsky, Aleksander; Fowst, Camilla; Hariharan, Subramanian; Huang, Bo; Di Pietro, Alessandra; Choueiri, Toni K. New England Journal Of Medicine 2019
16097 10.1056/nejmoa1816714 Pembrolizumab Plus Axitinib Versus Sunitinib For Advanced Renal-Cell Carcinoma Rini, Brian I.; Plimack, Elizabeth R.; Stus, Viktor; Gafanov, Rustem; Hawkins, Robert; Nosov, Dmitry; Pouliot, Frederic; Alekseev, Boris; Soulieres, Denis; Melichar, Bohuslav; Vynnychenko, Ihor; Kryzhanivska, Anna; Bondarenko, Igor; Azevedo, Sergio J.; Borchiellini, Delphine; Szczylik, Cezary; Markus, Maurice; Mcdermott, Raymond S.; Bedke, Jens; Tartas, Sophie; Chang, Yen-Hwa; Tamada, Satoshi; Shou, Qiong; Perini, Rodolfo F.; Chen, Mei; Atkins, Michael B.; Powles, Thomas New England Journal Of Medicine 2019
16204 10.1056/nejmoa2026982 Nivolumab Plus Cabozantinib Versus Sunitinib For Advanced Renal-Cell Carcinoma Choueiri, Toni K.; Powles, Thomas; Burotto, Mauricio; Escudier, Bernard; Bourlon, Maria T.; Zurawski, Bogdan; Oyervides Juarez, Victor M.; Hsieh, James J.; Basso, Umberto; Shah, Amishi Y.; Suarez, Cristina; Hamzaj, Alketa; Goh, Jeffrey C.; Barrios, Carlos; Richardet, Martin; Porta, Camillo; Kowalyszyn, Ruben; Feregrino, Juan P.; <U+017B>o<U+0142>nierek, Jakub; Pook, David; Kessler, Elizabeth R.; Tomita, Yoshihiko; Mizuno, Ryuichi; Bedke, Jens; Zhang, Joshua; Maurer, Matthew A.; Simsek, Burcin; Ejzykowicz, Flavia; Schwab, Gisela M.; Apolo, Andrea B.; Motzer, Robert J. New England Journal Of Medicine 2021
16228 10.1056/nejmoa2035716 Lenvatinib Plus Pembrolizumab Or Everolimus For Advanced Renal Cell Carcinoma Motzer, Robert; Alekseev, Boris; Rha, Sun-Young; Porta, Camillo; Eto, Masatoshi; Powles, Thomas; Grunwald, Viktor; Hutson, Thomas E.; Kopyltsov, Evgeny; Mendez-Vidal, Maria J.; Kozlov, Vadim; Alyasova, Anna; Hong, Sung-Hoo; Kapoor, Anil; Alonso Gordoa, Teresa; Merchan, Jaime R.; Winquist, Eric; Maroto, Pablo; Goh, Jeffrey C.; Kim, Miso; Gurney, Howard; Patel, Vijay; Peer, Avivit; Procopio, Giuseppe; Takagi, Toshio; Melichar, Bohuslav; Rolland, Frederic; De Giorgi, Ugo, 0000-0001-7520-2908; Wong, Shirley; Bedke, Jens; Schmidinger, Manuela; Dutcus, Corina E.; Smith, Alan D.; Dutta, Lea; Mody, Kalgi; Perini, Rodolfo F.; Xing, Dongyuan; Choueiri, Toni K. New England Journal Of Medicine 2021
16975 10.1093/annonc/mdz056 Renal Cell Carcinoma: Esmo Clinical Practice Guidelines For Diagnosis, Treatment And Follow-Up Escudier, B.; Porta, C.; Schmidinger, M.; Rioux-Leclercq, N.; Bex, A.; Khoo, V.; Grunwald, V.; Gillessen, S.; Horwich, A. Annals Of Oncology 2019
19231 10.1136/esmoopen-2020-001079 Nivolumab Plus Ipilimumab Versus Sunitinib For First-Line Treatment Of Advanced Renal Cell Carcinoma: Extended 4-Year Follow-Up Of The Phase Iii Checkmate 214 Trial Albiges, Laurence, 0000-0002-5734-3480; Tannir, Nizar M.; Burotto, Mauricio; Mcdermott, David; Plimack, Elizabeth R.; Barthelemy, Philippe; Porta, Camillo, 0000-0003-2412-1563; Powles, Thomas; Donskov, Frede; George, Saby; Kollmannsberger, Christian K.; Gurney, Howard; Grimm, Marc-Oliver; Tomita, Yoshihiko; Castellano, Daniel; Rini, Brian I.; Choueiri, Toni K.; Saggi, Shruti Shally; Mchenry, M. Brent; Motzer, Robert J. Esmo Open 2020
19274 10.1136/jitc-2020-000891 Survival Outcomes And Independent Response Assessment With Nivolumab Plus Ipilimumab Versus Sunitinib In Patients With Advanced Renal Cell Carcinoma: 42-Month Follow-Up Of A Randomized Phase 3 Clinical Trial Motzer, Robert J, 0000-0001-6925-2327; Escudier, Bernard; Mcdermott, David F; Aren Frontera, Osvaldo; Melichar, Bohuslav; Powles, Thomas; Donskov, Frede; Plimack, Elizabeth R; Barthelemy, Philippe; Hammers, Hans J; George, Saby; Grunwald, Viktor; Porta, Camillo; Neiman, Victoria; Ravaud, Alain; Choueiri, Toni K, 0000-0002-9201-3217; Rini, Brian I; Salman, Pamela; Kollmannsberger, Christian K; Tykodi, Scott S; Grimm, Marc-Oliver; Gurney, Howard; Leibowitz-Amit, Raya; Geertsen, Poul F; Amin, Asim; Tomita, Yoshihiko; Mchenry, M Brent; Saggi, Shruti Shally; Tannir, Nizar M Journal For Immunotherapy Of Cancer 2020
19535 10.1158/2159-8290.cd-18-0957 Transcriptomic Profiling Of The Tumor Microenvironment Reveals Distinct Subgroups Of Clear Cell Renal Cell Cancer: Data From A Randomized Phase Iii Trial Hakimi, A. Ari; Voss, Martin H., 0000-0003-0551-5807; Kuo, Fengshen, 0000-0003-1797-2896; Sanchez, Alejandro; Liu, Ming; Nixon, Briana G.; Vuong, Lynda; Ostrovnaya, Irina; Chen, Ying-Bei, 0000-0001-5207-3648; Reuter, Victor; Riaz, Nadeem; Cheng, Yuan; Patel, Parul; Marker, Mahtab; Reising, Albert; Li, Ming O.; Chan, Timothy A.; Motzer, Robert J., 0000-0001-6925-2327 Cancer Discovery 2019
20187 10.1186/s40425-018-0420-0 Safety And Efficacy Of Nivolumab In Combination With Sunitinib Or Pazopanib In Advanced Or Metastatic Renal Cell Carcinoma: The Checkmate 016 Study Amin, Asim; Plimack, Elizabeth R; Ernstoff, Marc S; Lewis, Lionel D; Bauer, Todd M; Mcdermott, David F; Carducci, Michael; Kollmannsberger, Christian; Rini, Brian I; Heng, Daniel Y C; Knox, Jennifer; Voss, Martin H; Spratlin, Jennifer; Berghorn, Elmer; Yang, Lingfeng; Hammers, Hans J Journal For Immunotherapy Of Cancer 2018
20325 10.1200/jco.2019.37.15_suppl.101 Biomarker Analyses From Javelin Renal 101: Avelumab + Axitinib (A+Ax) Versus Sunitinib (S) In Advanced Renal Cell Carcinoma (Arcc). Choueiri, Toni K.; Albiges, Laurence; Haanen, John B. A. G.; Larkin, James M.G.; Uemura, Motohide; Pal, Sumanta K.; Gravis, Gwenaelle; Campbell, Matthew T; Penkov, Konstantin; Lee, Jae-Lyun; Ching, Keith A.; Mu, Xinmeng Jasmine; Wang, Xiao; Zhang, Weidong; Wang, Jing; Chudnovsky, Aleksander; Di Pietro, Alessandra; Robbins, Paul B.; Motzer, Robert J. Journal Of Clinical Oncology 2019
20331 10.1200/jco.2019.37.15_suppl.4500 Pembrolizumab (Pembro) Plus Axitinib (Axi) Versus Sunitinib As First-Line Therapy For Metastatic Renal Cell Carcinoma (Mrcc): Outcomes In The Combined Imdc Intermediate/Poor Risk And Sarcomatoid Subgroups Of The Phase 3 Keynote-426 Study. Rini, Brian I.; Plimack, Elizabeth R.; Stus, Viktor; Gafanov, Rustem; Hawkins, Robert; Nosov, Dmitry; Pouliot, Frederic; Soulieres, Denis; Melichar, Bohuslav; Vynnychenko, Ihor; Azevedo, Sergio Jobim; Borchiellini, Delphine; Mcdermott, Raymond S.; Bedke, Jens; Tamada, Satoshi; Wan, Shuyan; Perini, Rodolfo F.; Chen, Mei; Atkins, Michael B.; Powles, Thomas Journal Of Clinical Oncology 2019